Key result
Clopidogrel response variability affects ~30% of patients, potentially attenuating clinical benefit against arterial thrombotic events.
Why the study?
The clinical benefit of clopidogrel may be attenuated by variability of response in up to 30% of patients, and the best laboratory procedure to screen for this variability remains undetermined.
Answers are grounded in this paper and cite their sources.
Up to 30% of patients exhibit variability in response to clopidogrel due to multiple mechanisms, highlighting the need for optimal laboratory screening procedures.
Clopidogrel has been shown to inhibit adenosine diphosphate-induced platelet aggregation and has been demonstrated to be effective in reducing the risk of arterial thrombotic events in several large clinical studies. However, the clinical benefit could be attenuated by the variability of response to the antiplatelet effects of clopidogrel in as many as 30% of patients. Multiple mechanisms likely contribute to clopidogrel variability of response, including inappropriate dosing or underdosing of clopidogrel, drug-drug interactions, and genetic polymorphisms. The best laboratory procedure to screen for possible clopidogrel variability of response remains to be determined.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2006) conducted a review in Arterial thrombotic events. Clopidogrel was evaluated. Clopidogrel response variability affects up to 30% of patients, potentially attenuating its clinical benefit in reducing arterial thrombotic events due to dosing, interactions, and genetics.
Synapse has enriched 10 related papers. Consider them for comparative context: